000169361 001__ 169361
000169361 005__ 20240112171833.0
000169361 0247_ $$2doi$$a10.3390/cells12010079
000169361 0247_ $$2pmid$$apmid:36611872
000169361 0247_ $$2pmc$$apmc:PMC9818422
000169361 0247_ $$2altmetric$$aaltmetric:141007309
000169361 037__ $$aDZNE-2023-00136
000169361 041__ $$aEnglish
000169361 082__ $$a570
000169361 1001_ $$0P:(DE-2719)2811277$$aNjavro, Jasenka$$b0$$eFirst author$$udzne
000169361 245__ $$aBeneficial Effect of ACI-24 Vaccination on Aβ Plaque Pathology and Microglial Phenotypes in an Amyloidosis Mouse Model.
000169361 260__ $$aBasel$$bMDPI$$c2022
000169361 3367_ $$2DRIVER$$aarticle
000169361 3367_ $$2DataCite$$aOutput Types/Journal article
000169361 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1673873794_16648
000169361 3367_ $$2BibTeX$$aARTICLE
000169361 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169361 3367_ $$00$$2EndNote$$aJournal Article
000169361 520__ $$aAmyloid-β (Aβ) deposition is an initiating factor in Alzheimer's disease (AD). Microglia are the brain immune cells that surround and phagocytose Aβ plaques, but their phagocytic capacity declines in AD. This is in agreement with studies that associate AD risk loci with genes regulating the phagocytic function of immune cells. Immunotherapies are currently pursued as strategies against AD and there are increased efforts to understand the role of the immune system in ameliorating AD pathology. Here, we evaluated the effect of the Aβ targeting ACI-24 vaccine in reducing AD pathology in an amyloidosis mouse model. ACI-24 vaccination elicited a robust and sustained antibody response in APPPS1 mice with an accompanying reduction of Aβ plaque load, Aβ plaque-associated ApoE and dystrophic neurites as compared to non-vaccinated controls. Furthermore, an increased number of NLRP3-positive plaque-associated microglia was observed following ACI-24 vaccination. In contrast to this local microglial activation at Aβ plaques, we observed a more ramified morphology of Aβ plaque-distant microglia compared to non-vaccinated controls. Accordingly, bulk transcriptomic analysis revealed a trend towards the reduced expression of several disease-associated microglia (DAM) signatures that is in line with the reduced Aβ plaque load triggered by ACI-24 vaccination. Our study demonstrates that administration of the Aβ targeting vaccine ACI-24 reduces AD pathology, suggesting its use as a safe and cost-effective AD therapeutic intervention.
000169361 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000169361 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000169361 650_2 $$2MeSH$$aMice
000169361 650_2 $$2MeSH$$aAnimals
000169361 650_2 $$2MeSH$$aMicroglia: metabolism
000169361 650_2 $$2MeSH$$aAmyloid beta-Protein Precursor: metabolism
000169361 650_2 $$2MeSH$$aMice, Transgenic
000169361 650_2 $$2MeSH$$aAmyloid beta-Peptides: metabolism
000169361 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000169361 650_2 $$2MeSH$$aAlzheimer Disease: therapy
000169361 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000169361 650_2 $$2MeSH$$aAmyloidosis: metabolism
000169361 650_2 $$2MeSH$$aPlaque, Amyloid: metabolism
000169361 650_2 $$2MeSH$$aPhenotype
000169361 650_2 $$2MeSH$$aVaccination
000169361 650_7 $$2Other$$aAlzheimer’s disease
000169361 650_7 $$2Other$$aACI-24
000169361 650_7 $$2Other$$aAlzheimer’s disease
000169361 650_7 $$2Other$$aAβ vaccine
000169361 650_7 $$2Other$$aimmunotherapy
000169361 650_7 $$2Other$$amicroglia
000169361 650_7 $$2NLM Chemicals$$aAmyloid beta-Protein Precursor
000169361 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000169361 650_7 $$2Other$$aAβ vaccine
000169361 7001_ $$aVukicevic, Marija$$b1
000169361 7001_ $$aFiorini, Emma$$b2
000169361 7001_ $$0P:(DE-2719)2813128$$aDinkel, Lina$$b3$$udzne
000169361 7001_ $$0P:(DE-2719)2810938$$aMüller, Stephan A$$b4$$udzne
000169361 7001_ $$0P:(DE-2719)2811640$$aBerghofer, Anna$$b5$$udzne
000169361 7001_ $$0P:(DE-2719)9001903$$aBordier, Chiara$$b6$$udzne
000169361 7001_ $$0P:(DE-2719)2812648$$aKozlov, Stanislav$$b7$$udzne
000169361 7001_ $$0P:(DE-2719)2812038$$aHalle, Annett$$b8$$udzne
000169361 7001_ $$0P:(DE-2719)9002284$$aBuschmann, Katrin$$b9$$udzne
000169361 7001_ $$0P:(DE-2719)9000368$$aCapell, Anja$$b10$$udzne
000169361 7001_ $$0P:(DE-2719)2812582$$aGiudici, Camilla$$b11$$udzne
000169361 7001_ $$0P:(DE-2719)9000433$$aWillem, Michael$$b12$$udzne
000169361 7001_ $$0P:(DE-2719)2812867$$aFeederle, Regina$$b13$$udzne
000169361 7001_ $$0P:(DE-2719)2181459$$aLichtenthaler, Stefan F$$b14
000169361 7001_ $$aBabolin, Chiara$$b15
000169361 7001_ $$aMontanari, Paolo$$b16
000169361 7001_ $$aPfeifer, Andrea$$b17
000169361 7001_ $$aKosco-Vilbois, Marie$$b18
000169361 7001_ $$0P:(DE-2719)2442036$$aTahirovic, Sabina$$b19$$eLast author$$udzne
000169361 773__ $$0PERI:(DE-600)2661518-6$$a10.3390/cells12010079$$gVol. 12, no. 1, p. 79 -$$n1$$p79$$tCells$$v12$$x2073-4409$$y2022
000169361 8564_ $$uhttps://pub.dzne.de/record/169361/files/DZNE-2023-00136%20SUP.zip
000169361 8564_ $$uhttps://pub.dzne.de/record/169361/files/DZNE-2023-00136.pdf$$yOpenAccess
000169361 8564_ $$uhttps://pub.dzne.de/record/169361/files/DZNE-2023-00136.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000169361 909CO $$ooai:pub.dzne.de:169361$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000169361 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811277$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000169361 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2813128$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000169361 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810938$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000169361 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811640$$aExternal Institute$$b5$$kExtern
000169361 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001903$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000169361 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812648$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000169361 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812038$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000169361 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002284$$aExternal Institute$$b9$$kExtern
000169361 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000368$$aExternal Institute$$b10$$kExtern
000169361 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812582$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000169361 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000433$$aExternal Institute$$b12$$kExtern
000169361 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812867$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000169361 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2181459$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000169361 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2442036$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b19$$kDZNE
000169361 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000169361 9141_ $$y2022
000169361 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000169361 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000169361 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000169361 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000169361 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000169361 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELLS-BASEL : 2021$$d2022-11-30
000169361 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-07T08:42:17Z
000169361 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-07T08:42:17Z
000169361 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000169361 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000169361 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000169361 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000169361 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000169361 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000169361 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCELLS-BASEL : 2021$$d2022-11-30
000169361 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000169361 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000169361 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000169361 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-07T08:42:17Z
000169361 9201_ $$0I:(DE-2719)1140003$$kAG Tahirovic$$lEx vivo models$$x0
000169361 9201_ $$0I:(DE-2719)1110006$$kAG Lichtenthaler$$lNeuroproteomics$$x1
000169361 9201_ $$0I:(DE-2719)1013034$$kAG Halle$$lMicroglia and Neuroinflammation$$x2
000169361 9201_ $$0I:(DE-2719)1110007$$kAG Haass old$$lALS, FTLD and Zebrafish models$$x3
000169361 980__ $$ajournal
000169361 980__ $$aVDB
000169361 980__ $$aUNRESTRICTED
000169361 980__ $$aI:(DE-2719)1140003
000169361 980__ $$aI:(DE-2719)1110006
000169361 980__ $$aI:(DE-2719)1013034
000169361 980__ $$aI:(DE-2719)5000015
000169361 9801_ $$aFullTexts